Nanotechnology Now - Press Release: Cancer Therapeutics Announces Letter of Intent With NanoTherapies, LLC: Company Will Increase Its Stake to 51 Percent After Finalizing Latest Agreement

Home > Press > Cancer Therapeutics Announces Letter of Intent With NanoTherapies, LLC: Company Will Increase Its Stake to 51 Percent After Finalizing Latest Agreement

Abstract:
Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, LLC which would give Cancer Therapeutics a total of 51 percent and controlling interest of NanoTherapies. Terms of the agreement, which include six million restricted shares to NanoTherapies, are subject to formal approval by the Managing Member and Governing Board of Directors of NanoTherapies, LLC. In addition, a full audit of NanoTherapies needs to be completed as well for a binding agreement.

Cancer Therapeutics Announces Letter of Intent With NanoTherapies, LLC: Company Will Increase Its Stake to 51 Percent After Finalizing Latest Agreement

Salt Lake City, UT | Posted on October 18th, 2009

Recently, Cancer Therapeutics announced the completion of a 25 percent stake in NanoTherapies, making it the company's first acquisition. Chene Gardner, President and CEO of Cancer Therapeutics, said he anticipates finalizing the new agreement to come within the next 90 days.

NanoTherapies develops life-changing therapies for cancer treatment based on an evolving set of intellectual properties and patents derived from the exploitation of calcium phosphate nanoparticles for therapeutic and diagnostic applications.

####

About Cancer Therapeutics, Inc.
Cancer Therapeutics, Inc. is a biotechnology business incubator, with a specific emphasis on disruptive treatments and nanotechnology. It seeks out disruptive cancer research and technology opportunities to invest in, develop, and commercialize. The end result will be therapies, treatments, and pharmaceuticals targeted at more efficiently and effectively attacking cancer. CTI seeks partners to co-develop drugs in various stages in our pipeline.

Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.

Contacts:
Investor Relations
David Donlin
Cervelle Group
Phone: 407-614-5959 ext. 223

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: